201 related articles for article (PubMed ID: 7658093)
1. The absence of loss of antibodies of high affinity to human immunodeficiency virus (HIV) is associated with disease progression in HIV-1-infected patients.
Chargelegue D; Stanley CM; O'Toole CM; Colvin BT; Steward MW
J Infect Dis; 1995 Sep; 172(3):897-8. PubMed ID: 7658093
[No Abstract] [Full Text] [Related]
2. The affinity of IgG antibodies to gag p24 and p17 in HIV-1-infected patients correlates with disease progression.
Chargelegue D; Stanley CM; O'Toole CM; Colvin BT; Steward MW
Clin Exp Immunol; 1995 Feb; 99(2):175-81. PubMed ID: 7851008
[TBL] [Abstract][Full Text] [Related]
3. A longitudinal study of the IgG antibody response to HIV-1 p17 gag protein in HIV-1+ patients with haemophilia: titre and avidity.
Chargelegue D; O'Toole CM; Colvin BT
Clin Exp Immunol; 1993 Sep; 93(3):331-6. PubMed ID: 8370162
[TBL] [Abstract][Full Text] [Related]
4. Differential maturation of avidity of IgG antibodies to gp41, p24 and p17 following infection with HIV-1.
Thomas HI; Wilson S; O'Toole CM; Lister CM; Saeed AM; Watkins RP; Morgan-Capner P
Clin Exp Immunol; 1996 Feb; 103(2):185-91. PubMed ID: 8565298
[TBL] [Abstract][Full Text] [Related]
5. A 7-year analysis of anti-Gag (p17 and p24) antibodies in HIV-1-seropositive patients with haemophilia: immunoglobulin G titre and avidity are early predictors of clinical course.
Chargelegue D; Colvin BT; O'Toole CM
AIDS; 1993 Nov; 7 Suppl 2():S87-90. PubMed ID: 7909231
[TBL] [Abstract][Full Text] [Related]
6. An ELISA-inhibition assay for antibody to human immunodeficiency virus core antigen (p24).
Povolotsky J; Gold JW; Darminin P; Chein N; Baron P; Armstrong D
J Virol Methods; 1990 Oct; 30(1):109-14. PubMed ID: 2128300
[TBL] [Abstract][Full Text] [Related]
7. Prevalence and persistence of antibody titers to recombinant HIV-1 core and matrix proteins in HIV-1 infection.
Janvier B; Mallet F; Cheynet V; Dalbon P; Vernet G; Besnier JM; Choutet P; Goudeau A; Mandrand B; Barin F
J Acquir Immune Defic Syndr (1988); 1993 Aug; 6(8):898-903. PubMed ID: 8315575
[TBL] [Abstract][Full Text] [Related]
8. Enhancement of cellular and humoral immune responses to human immunodeficiency virus type 1 Gag and Pol by a G/P-92 fusion protein expressing highly immunogenic Gag p17/p24 and Pol p51 antigens.
Kmieciak D; Bolesta E; Naito T; Gzyl J; Kaneko Y; Kozbor D
J Hum Virol; 2001; 4(6):306-16. PubMed ID: 12082397
[TBL] [Abstract][Full Text] [Related]
9. Optimal conditions of immune complex transfer enzyme immunoassays for antibody IgGs to HIV-1 using recombinant p17, p24, and reverse transcriptase as antigens.
Hashida S; Ishikawa S; Hashinaka K; Nishikata I; Oka S; Shimada K; Saito A; Takamizawa A; Shinagawa H; Ishikawa E
J Clin Lab Anal; 1998; 12(2):98-107. PubMed ID: 9524294
[TBL] [Abstract][Full Text] [Related]
10. Decline in CTL and antibody responses to HIV-1 p17 and p24 antigens in HIV-1-infected hemophiliacs irrespective of disease progression. A 5-year follow-up study.
O'Toole CM; Lowdell MW; Chargelegue D; Colvin BT
AIDS Res Hum Retroviruses; 1992 Aug; 8(8):1361-8. PubMed ID: 1281655
[TBL] [Abstract][Full Text] [Related]
11. Fine specificity of IgG subclass response to group antigens in HIV-1-infected patients.
Broliden PA; Morfeldt-Månsson L; Rosen J; Jondal M; Wahren B
Clin Exp Immunol; 1989 May; 76(2):216-21. PubMed ID: 2503275
[TBL] [Abstract][Full Text] [Related]
12. Earlier detection of human immunodeficiency virus type 1 p24 antigen and immunoglobulin G and M antibodies to p17 antigen in seroconversion serum panels by immune complex transfer enzyme immunoassays.
Hashida S; Ishikawa S; Hashinaka K; Nishikata I; Oka S; Ishikawa E
Clin Diagn Lab Immunol; 2000 Nov; 7(6):872-81. PubMed ID: 11063490
[TBL] [Abstract][Full Text] [Related]
13. Neutralizing antibodies as a prognostic indicator in the progression of acquired immune deficiency syndrome (AIDS)-related disorders: a double-blind study.
Sei Y; Tsang PH; Roboz JP; Sarin PS; Wallace JI; Bekesi JG
J Clin Immunol; 1988 Nov; 8(6):464-72. PubMed ID: 3146584
[TBL] [Abstract][Full Text] [Related]
14. Konzo, an epidemic spastic paraparesis in Africa, is not associated with antibodies to HTLV-I, HIV, or HIV gag-encoded proteins.
Tylleskär T; Banea M; Böttiger B; Thorstensson R; Biberfeld G; Rosling H
J Acquir Immune Defic Syndr Hum Retrovirol; 1996 Jul; 12(3):317-8. PubMed ID: 8673538
[No Abstract] [Full Text] [Related]
15. [Anti-HIV-1 p17 antibody as anti-HIV agent].
Tsuchie H; Tochikura A; Kageyama S; Kurimura T
Nihon Rinsho; 1993 Sep; 51 Suppl():213-8. PubMed ID: 8271386
[No Abstract] [Full Text] [Related]
16. Persistent antibody responses but declining cytotoxic T-lymphocyte responses to multiple human immunodeficiency virus type 1 antigens in a long-term nonprogressing individual with a defective p17 proviral sequence and no detectable viral RNA expression.
Binley JM; Jin X; Huang Y; Zhang L; Cao Y; Ho DD; Moore JP
J Virol; 1998 Apr; 72(4):3472-4. PubMed ID: 9525685
[TBL] [Abstract][Full Text] [Related]
17. Antibody recognition of synthetic peptides mimicking immunodominant regions of HIV-1 p24 and p17 proteins.
Lottersberger J; Salvetti JL; Beltramini LM; Tonarelli G
Rev Argent Microbiol; 2004; 36(4):151-7. PubMed ID: 15786866
[TBL] [Abstract][Full Text] [Related]
18. Prevalence of antibodies to the core protein P17, a serological marker during HIV-1 infection.
Mehta SU; Rupprecht KR; Hunt JC; Kramer DE; McRae BJ; Allen RG; Dawson GJ; Devare SG
AIDS Res Hum Retroviruses; 1990 Apr; 6(4):443-54. PubMed ID: 1692727
[TBL] [Abstract][Full Text] [Related]
19. Discriminating between protective and enhancing HIV antibodies.
Bernard J; Reveil B; Najman I; Liautaud-Roger F; Fouchard M; Picard O; Cattan A; Mabondzo A; Laverne S; Gallo RC
AIDS Res Hum Retroviruses; 1990 Feb; 6(2):243-9. PubMed ID: 2109624
[TBL] [Abstract][Full Text] [Related]
20. Vaccine-induced HIV seropositivity: a problem on the rise.
Van Braeckel E; Koutsoukos M; Bourguignon P; Clement F; McNally L; Leroux-Roels G
J Clin Virol; 2011 Apr; 50(4):334-7. PubMed ID: 21300566
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
